COVID-19 after rituximab therapy in cSLE patients

• Príomhchruthaitheoirí: Meghan Corrigan Nelson (Údar), Cynthia K. Manos (Údar), Elaine Flanagan (Údar), Sampath Prahalad (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: SAGE Publishing, 2023-06-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Childhood-onset systemic lupus erythematosus (cSLE) is an autoimmune disease associated with significant morbidity and mortality. Rituximab is a B-cell depleting therapy utilized in the treatment of SLE. In adults, rituximab has been associated with increased risk of adverse outcomes in patients who...